China’s brain–computer interface (BCI) sector has taken a conspicuous step toward commercialization after Shanghai‑based Jieti Medical (阶梯医疗) closed a RMB 500 million strategic funding round led by Alibaba, with state‑linked investor Guotou Chuanghe and returning backers including Tencent and several venture funds participating. The financing brings Jieti’s fundraising in the past year to more than RMB 1.1 billion and marks the first time China’s two internet giants have both invested in the same domestic invasive BMI enterprise, signalling big‑tech confidence in the clinical path of neurotech.
Jieti, founded in 2021, develops minimally invasive implantable BCIs and a supporting stack of electrodes, system hardware, algorithms and surgical robotics. The company says it operates on two business tracks—“brain control” interfaces that restore motor and communication functions, and “neuro‑modulation” therapies aimed at neurological disorders—and has rapidly advanced from lab prototypes to repeated human implants.
Clinical milestones have accelerated. Jieti reported that a second invasive BCI trial completed successfully at the end of 2025: a patient paralysed by a high spinal cord injury was implanted in June 2025 and, after weeks of training, regained stable control of a computer cursor and tablet, and later performed real‑world tasks such as operating a wheelchair and directing a robotic pet with sub‑100 millisecond end‑to‑end response times. A third clinical case concluded in October 2025, and in early 2026 the company implanted what it describes as a domestically first 256‑channel wireless high‑throughput invasive BCI (WRS02), validating brain‑control function in humans.
Jieti has announced an ambitious scale‑up: a mid‑2026 start to a large, multi‑centre registration trial with a target of roughly 40 patient implants during the year. If achieved, that would place Jieti’s accumulated implant count close to—or potentially ahead of—Neuralink’s public clinical totals, a point the company highlights to signal China’s narrowing gap with US rivals on human trials.
The broader policy and market context strengthens Jieti’s case. Beijing for the first time listed brain‑computer interfaces in the 2026 government work report among industries to be cultivated alongside quantum technologies, 6G and embodied intelligence. The China Academy of Information and Communications Technology projects the domestic BCI industry could reach RMB 10–14 billion (100–140 亿元) by 2030, helping to attract capital and regulatory attention.
Investors and founders underline the convergence of medical and engineering expertise as the sector’s competitive edge. Jieti’s co‑founders are young, Western‑trained biomedical engineers who emphasise an integrated approach spanning hardware, software and surgical technique. Yet the path to commercial success remains laden with hurdles: larger multi‑centre registration trials, long‑term safety and durability data, regulatory approvals, manufacturing scale‑up, reimbursement pathways and ethical oversight will all determine whether the field’s scientific promise becomes durable medical practice.
For international observers the rapid pace of Chinese clinical activity is notable. Domestic firms already span non‑invasive to fully invasive approaches and benefit from coordinated policy support and concentrated capital. That mix could accelerate clinical throughput and product iteration, intensifying competition with Western start‑ups and raising fresh regulatory and geopolitical questions about standards, cross‑border collaboration and potential dual‑use applications of neurotechnology.